BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 14992907)

  • 21. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
    Cugno M; Mari D; Meroni PL; Gronda E; Vicari F; Frigerio M; Coppola R; Bottasso B; Borghi MO; Gregorini L
    Br J Haematol; 2004 Jul; 126(1):85-92. PubMed ID: 15198737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
    Mehta P; Parker RI
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
    Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
    Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
    J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).
    Hazama S; Eishi K; Yamachika S; Noguchi M; Ariyoshi T; Takai H; Odate T; Matsukuma S; Onohara D; Yanatori M
    Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):90-6. PubMed ID: 15209550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK; Mestries JC; Gascon MP; Ythier A
    Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemostasis activation during esophageal variceal sclerotherapy with thrombin in cirrhotics.
    Fujii Y; Sugawa C; Ozawa T; Nakumura R; Brown-Castillo J; Mammen EF
    Am Surg; 1991 Apr; 57(4):222-5. PubMed ID: 1711300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.
    Paparella D; Semeraro F; Scrascia G; Galeone A; Ammollo CT; Kounakis G; de Luca Tupputi Schinosa L; Semeraro N; Colucci M
    Ann Thorac Surg; 2010 Feb; 89(2):421-7. PubMed ID: 20103314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
    Chandler WL; Velan T
    Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
    Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
    Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
    Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
    J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer.
    Nanninga PB; van Teunenbroek A; Veenhof CH; Büller HR; ten Cate JW
    Thromb Haemost; 1990 Nov; 64(3):361-4. PubMed ID: 1710832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.